Hippo Pathway in Regulating Drug Resistance of Glioblastoma
Glioblastoma (GBM) represents the most common and malignant tumor of the Central Nervous System (CNS), affecting both children and adults. GBM is one of the deadliest tumor types and it shows a strong multidrug resistance (MDR) and an immunosuppressive microenvironment which remain a great challenge...
Main Authors: | Giacomo Casati, Laura Giunti, Anna Lisa Iorio, Arianna Marturano, Luisa Galli, Iacopo Sardi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/24/13431 |
Similar Items
-
Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma
by: Kshama Gupta, et al.
Published: (2020-05-01) -
CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway
by: Xin Wang, et al.
Published: (2021-09-01) -
Exosomal B7–H4 from irradiated glioblastoma cells contributes to increase FoxP3 expression of differentiating Th1 cells and promotes tumor growth
by: Yunhong Tian, et al.
Published: (2022-10-01) -
APLN/APLNR Signaling Controls Key Pathological Parameters of Glioblastoma
by: Roland E. Kälin, et al.
Published: (2021-08-01) -
The Hippo pathway in endometrial cancer: a potential therapeutic target?
by: Xinyun Shen, et al.
Published: (2023-10-01)